Clinical Trials Logo

Acute Aortic Syndrome clinical trials

View clinical trials related to Acute Aortic Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT04751058 Recruiting - Gene Abnormality Clinical Trials

Genetic Profile in Patients With Aortic Syndrome

GEN-AOR
Start date: February 27, 2021
Phase:
Study type: Observational

The overall prevalence has increased significantly in the general population, which may be due in part to advances in diagnostic techniques, such as improved imaging techniques. Aortic dissection (AD) can cause sudden cardiac death (SCD). Approximately 95% of thoracic AAS are clinically "silent" until a life-threatening complication arises in an unpredictable manner and presents as sudden cardiac death. The peak incidence of death caused by aortic dissection occurs within 48 hours, therefore, timely diagnosis is essential and saves lives. We have traditionally associated as risk factors in patients with ASA long-term arterial hypertension, present in 66-75% of cases, smoking, dyslipidemia or atherosclerotic disease. Likewise, any condition that alters the structure of the aorta such as: collagen diseases, aneurysms, bicuspid aorta, and manipulation of the thoracic aorta (cardiac surgery, 18%, or percutaneous intervention that can injure the intima) is involved in ASA. In addition to the well-known hereditary syndromes that affect collagen (Marfan, Elher-Danlos ...) there is a clear familial aggregation: 13-19% of patients without identifiable syndrome have first-degree relatives with thoracic aortic aneurysms or ICD, something that has been called "thoracic aortic dissection and familial aneurysm syndrome." Notable achievements have been made in the discovery of genetic mutations associated with SAA and key regulatory molecules involved, including the extracellular matrix (ECM), cytoskeletal proteins, and the TGF-β signaling pathway. Identification of the causative gene is advantageous for both patients and their families, especially those who do not show symptoms. The specific underlying genotype could benefit the process of diagnosis, surveillance and surgery, with the aim of reducing morbidity and mortality

NCT ID: NCT04711889 Enrolling by invitation - Aortic Dissection Clinical Trials

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (5A Plan) II

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Acute Aortic Syndrome (AAS) is a common feature of acute aortic wall events, including aortic dissection, intramural hematoma, aortic ulceration and aortic trauma, and occurs in up to 35 cases per 100,000 cases per year between the ages of 65 and 75 years. Ulinastatin has antiinflammatory activity and suppresses the infiltration of neutrophils and the release of elastase and chemical mediators from neutrophils. Recent studies have shown that ulinastatin may be cytoprotective against ischemia-reperfusion injury in the liver, kidney, heart, and lung. The authors aim to examine the association between decreased release of inflammatory response to urinary trypsin inhibitor treatment and decreased myocardial and lung injury after acute aortic syndrome surgery.

NCT ID: NCT04699279 Recruiting - Clinical trials for Acute Aortic Syndrome

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (5A Plan)

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Acute Aortic Syndrome (AAS) is a common feature of acute aortic wall events, including aortic dissection, intramural hematoma, aortic ulceration and aortic trauma, and occurs in up to 35 cases per 100,000 cases per year between the ages of 65 and 75 years. Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, the authors hypothesized that people with acute aortic syndrome but without hyperlipidemia might benefit from statin treatment.

NCT ID: NCT04430400 Recruiting - Clinical trials for Acute Aortic Syndrome

Pre-test Probability, FOCUS and D-dimer for Acute Aortic Syndromes

PROFUNDUS
Start date: September 1, 2020
Phase:
Study type: Observational [Patient Registry]

Observational, prospective, multicentre, international, non-profit, investigator-driven, diagnostic accuracy study performed in several international EDs. The aim of the study will be to evaluate the performance of an integrated algorithm based on aortic dissection risk score, focus cardiac ultrasound and D-dimer to rule-in and -out acute aortic syndromes. The final diagnosis will be established after review all available hospital clinical data and one month follow-up.

NCT ID: NCT03647566 Suspended - Aortic Dissection Clinical Trials

18F Sodium Fluoride PET/CT in Acute Aortic Syndrome

FAASt
Start date: October 1, 2018
Phase:
Study type: Observational

The purpose of this study is to determine whether Sodium Fluoride imaging (using Positron Emission Tomography-Computed Tomography - PET-CT) is able to predict disease progression in acute aortic syndrome.

NCT ID: NCT02273245 Completed - Clinical trials for Acute Aortic Syndrome

Is a Pre-contrast Scan Necesary to Diagnose Acute Aortic Syndrome?

Start date: January 2015
Phase: N/A
Study type: Observational

Acute Aortic Syndrome (AAS) is a potentially life-threatening cause of sudden, severe chest pain. There are several possible underlying causes, which cannot be distinguished from one another at the bedside. Current practice is to image this with two CT scans of the chest, one before injection of a contrast dye into the blood stream and then one after. With the advancement of CT scanner technology, improvements in software interpretation and screen resolution, the investigators hypothesise that performing the contrast scan on its own is diagnostically equivalent to both the pre- and contrast scans

NCT ID: NCT01259843 Completed - Clinical trials for Acute Aortic Syndrome

French National Observatory of Aortic Syndromes

ONSAA
Start date: August 2008
Phase:
Study type: Observational

The study examined the clinical characteristics and conditions of care for patients with acute aortic syndrome (AAS) that will identify patients at risk for increased morbidity and mortality and provide a basis for the eventual achievement of specific studies on the optimal therapeutic management according to different risk profiles. The aim of the Observatory is to provide a photograph "size" of practices in France at present, both in the larger centers than in smaller and optimize diagnostic and therapeutic currently available by the activation pathways of rational management.